© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Cerus Corporation (CERS) stock surged +2.69%, trading at $1.91 on NASDAQ, up from the previous close of $1.86. The stock opened at $1.87, fluctuating between $1.86 and $1.94 in the recent session.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Employees | 625 |
Beta | 1.2 |
Sales or Revenue | $156.37M |
5Y Sales Change% | 0.863% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Devices |
Cerus Corporation (NASDAQ: CERS) stock price is $1.91 in the last trading session. During the trading session, CERS stock reached the peak price of $1.94 while $1.86 was the lowest point it dropped to. The percentage change in CERS stock occurred in the recent session was 2.69% while the dollar amount for the price change in CERS stock was $0.05.
The NASDAQ listed CERS is part of Medical - Devices industry that operates in the broader Healthcare sector. Cerus Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Carol M. Moore
Senior Vice President of Regulatory Affairs, Quality & Clinical
Lainie Corten
Vice President of Global Marketing
Ms. Chrystal N. Menard
Chief Legal Officer & Gen. Counsel
Dr. Laurence M. Corash
Co-Founder & Chief Scientific Officer
Ms. Lori L. Roll
Vice President of Admin. & Corporation Sec.
Mr. William M. Greenman
Pres, Chief Executive Officer & Director
Mr. Vivek K. Jayaraman
Chief Operating Officer
Ms. Chrystal Jensen
Chief Legal Officer & Gen. Counsel
Dr. Richard J. Benjamin
Chief Medical Officer
Mr. Kevin D. Green
Vice President of Fin. & Chief Financial Officer
CERS's closing price is 34.78% higher than its 52-week low of $1.38 where as its distance from 52-week high of $2.59 is -28.18%.
Number of CERS employees currently stands at 625.
Official Website of CERS is: https://www.cerus.com
CERS could be contacted at phone 925 288 6000 and can also be accessed through its website. CERS operates from 1220 Concord Avenue, Concord, CA 94520, United States.
CERS stock volume for the day was 229.21K shares. The average number of CERS shares traded daily for last 3 months was 1.44M.
The market value of CERS currently stands at $354.72M with its latest stock price at $1.91 and 185.72M of its shares outstanding.